Theranexus SA Total Liabilities
Theranexus SA total liabilities. Based on the latest financial reports, Theranexus SA (ALTHX) has total liabilities worth €7.64 Million EUR (≈ $8.94 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Theranexus SA to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Theranexus SA (2015–2025)
Total liabilities of Theranexus SA from 2015 to 2025. This chart illustrates how Theranexus SA's total liabilities have evolved over time, based on quarterly financial data. Explore Theranexus SA (ALTHX) long-term investment share to see how much of total assets are deployed in long-term investments.
Theranexus SA Competitors by Total Liabilities
The table below lists competitors of Theranexus SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cherrybro co.Ltd
KQ:066360
|
Korea | ₩188.30 Billion |
|
Byuksan Corp
KO:007210
|
Korea | ₩303.73 Billion |
|
Neontech Co. Ltd
KQ:306620
|
Korea | ₩122.66 Billion |
|
Strongpoint ASA
OL:STRO
|
Norway | Nkr529.41 Million |
|
Toba Pulp Lestari Tbk
JK:INRU
|
Indonesia | Rp6.65 Trillion |
|
Griñó Ecologic S.A
MC:GRI
|
Spain | €30.85 Million |
|
WooGene B&G Co. Ltd
KQ:018620
|
Korea | ₩50.21 Billion |
|
Asahi Songwon Colors Limited
NSE:ASAHISONG
|
India | Rs2.82 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Theranexus SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Theranexus SA.
Liquidity & Leverage Metrics
Theranexus SA Total Liabilities Ratios Explained
Theranexus SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theranexus SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theranexus SA (2015–2025)
The table below shows the annual total liabilities of Theranexus SA from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.64 Million ≈ $8.94 Million |
+41.64% |
| 2024-12-31 | €5.40 Million ≈ $6.31 Million |
+7.58% |
| 2023-12-31 | €5.02 Million ≈ $5.86 Million |
-20.70% |
| 2022-12-31 | €6.33 Million ≈ $7.40 Million |
-5.70% |
| 2021-12-31 | €6.71 Million ≈ $7.84 Million |
-6.67% |
| 2020-12-31 | €7.19 Million ≈ $8.40 Million |
+33.24% |
| 2019-12-31 | €5.39 Million ≈ $6.31 Million |
-0.83% |
| 2018-12-31 | €5.44 Million ≈ $6.36 Million |
+226.73% |
| 2017-12-31 | €1.66 Million ≈ $1.95 Million |
-40.35% |
| 2016-12-31 | €2.79 Million ≈ $3.26 Million |
+165.91% |
| 2015-12-31 | €1.05 Million ≈ $1.23 Million |
-- |
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company… Read more